Silverarc Capital Management, LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Silverarc Capital Management, LLC reported 67 stock positions worth $443.7 million. Its top holding was Nuvalent Class A (NUVL) at 8.6% of the portfolio, followed by Merus (MRUS, 7.2%) and Insmed (INSM, 5.7%). Compared with Q2 2024, it opened 13 new positions, sold out of 11, added to 27 and reduced 17. The biggest buy was Insmed (INSM, shares +148%) and the biggest sale an exit from Morphic (MORF).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001816307
- Portfolio Value
- $443.7M (Q3 2024)
- SEC Filing
- 0001420506-24-002416 ↗ filed Nov 14, 2024
Holdings Value
Holdings 67 stocks · $443.7M
| NUVL Nuvalent Inc. Class A | 8.56% | 371,441 | $38.0M | Reduce -20.2% |
| MRUS Merus NV | 7.15% | 635,439 | $31.7M | Add +1.9% |
| INSM Insmed Inc. | 5.72% | 347,695 | $25.4M | Add +148.3% |
| RNAM Avidity Biosciences Inc. | 4.92% | 475,555 | $21.8M | Reduce -8.2% |
| ERAS Erasca Inc. | 4.27% | 6,946,488 | $19.0M | Reduce -11.1% |
| AKRO Akero Therapeutics Inc. | 4.14% | 639,840 | $18.4M | Add +2.4% |
| VCYT Veracyte Inc. | 3.61% | 470,565 | $16.0M | Add +66.7% |
| RYTM Rhythm Pharmaceuticals Inc. | 3.02% | 255,578 | $13.4M | Add +38.4% |
| COGT Cogent Biosciences Inc. | 2.97% | 1,221,362 | $13.2M | Add +1.3% |
| ITCI Intra-Cellular Therapies Inc. | 2.76% | 167,110 | $12.2M | Reduce -13.1% |
| CNTA Centessa Pharmaceuticals Ltd. | 2.68% | 744,592 | $11.9M | New |
| URGN Urogen Pharma Ltd. | 2.58% | 901,129 | $11.4M | Reduce -18.2% |
| ORIC Oric Pharmaceuticals Inc. | 2.54% | 1,099,490 | $11.3M | Add +2.2% |
| PSTX Poseida Therapeutics Inc. | 2.38% | 3,687,548 | $10.5M | Add +2.2% |
| VRNA Verona Pharma Ltd. | 2.26% | 348,866 | $10.0M | Add +14.5% |
| ALNY Alnylam Pharmaceuticals Inc. | 2.22% | 35,774 | $9.8M | Reduce -0.6% |
| GERN Geron Corp. | 1.84% | 1,801,561 | $8.2M | Add +80.3% |
| SNDX Syndax Pharmaceuticals Inc. | 1.64% | 378,746 | $7.3M | Add +2.4% |
| PCVX Vaxcyte Inc. | 1.56% | 60,500 | $6.9M | Add +2320.0% |
| KALV Kalvista Pharmaceuticals Inc. | 1.50% | 574,558 | $6.7M | Add +2.4% |
| PTGX Protagonist Therapeutics Inc. | 1.49% | 146,657 | $6.6M | New |
| CCCC C4 Therapeutics Inc. | 1.47% | 1,147,891 | $6.5M | Reduce -20.4% |
| SRPT Sarepta Therapeutics Inc. | 1.44% | 51,245 | $6.4M | Add +22.0% |
| BDSX Biodesix Inc. | 1.43% | 3,561,094 | $6.3M | Add +96.9% |
| ELUT Elutia Inc. | 1.41% | 1,645,808 | $6.3M | Add +2.6% |
| ADCT Adc Therapeutics SA | 1.27% | 1,795,080 | $5.7M | Add +1.5% |
| GOSS Gossamer Bio Inc. | 1.25% | 5,645,352 | $5.6M | Add +2.6% |
| OLMA Olema Pharmaceuticals Inc. | 1.22% | 455,082 | $5.4M | Reduce -16.8% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 1.21% | 513,369 | $5.4M | Add +2.7% |
| ABVX Abivax SA-ADR | 1.20% | 461,660 | $5.3M | Add +1.3% |
| WVE Wave Life Sciences Ltd. | 1.16% | 627,552 | $5.1M | Add +26.7% |
| IRON Disc Medicine Inc. | 1.15% | 103,862 | $5.1M | Add +2.6% |
| BHVN Biohaven Ltd. | 1.12% | 99,566 | $5.0M | Reduce -0.4% |
| CLDX Celldex Therapeutics Inc. | 1.11% | 145,000 | $4.9M | Reduce -61.3% |
| LBPH Longboard Pharmaceuticals Inc. | 0.93% | 124,353 | $4.1M | Add +1.2% |
| BIIB Biogen Inc. | 0.87% | 19,940 | $3.9M | Add +3.0% |
| PRAX Praxis Precision Medicines I | 0.87% | 67,045 | $3.9M | Reduce -0.4% |
| MODULAR MED INC | 0.73% | 1,440,000 | $3.2M | Add +60.0% |
| SLDB Solid Biosciences Inc. | 0.72% | 457,739 | $3.2M | Reduce -3.2% |
| BNTX Biontech SE-ADR | 0.70% | 26,083 | $3.1M | New |
| GPCR Structure Therapeutics Inc. | 0.70% | 70,516 | $3.1M | No change |
| MERSANA THERAPEUTICS INC | 0.68% | 1,585,786 | $3.0M | Reduce -36.6% |
| RLAY Relay Therapeutics Inc. | 0.67% | 419,242 | $3.0M | New |
| TELA Tela Bio Inc. | 0.64% | 1,124,928 | $2.8M | Add +12.5% |
| CGEN Compugen Ltd. | 0.61% | 1,501,113 | $2.7M | No change |
| CERS Cerus Corp. | 0.59% | 1,495,329 | $2.6M | Add +2.0% |
| ZVRA Zevra Therapeutics Inc. | 0.55% | 350,000 | $2.4M | New |
| CATX Perspective Therapeutics Inc. | 0.51% | 167,986 | $2.2M | Reduce -35.4% |
| BIOA Bioage Labs Inc. | 0.47% | 100,000 | $2.1M | New |
| UNICYCIVE THERAPEUTICS INC | 0.37% | 4,000,000 | $1.6M | New |
| TRVI Trevi Therapeutics Inc. | 0.36% | 482,575 | $1.6M | Reduce -42.8% |
| XNCR Xencor Inc. | 0.34% | 75,507 | $1.5M | New |
| TARS Tarsus Pharmaceuticals Inc. | 0.30% | 40,000 | $1.3M | No change |
| KOD Kodiak Sciences Inc. | 0.29% | 500,000 | $1.3M | Reduce -52.9% |
| EVGN Evogene Ltd. | 0.21% | 307,974 | $945K | No change |
| MTEMQ Molecular Templates Inc. | 0.20% | 623,838 | $876K | No change |
| APLT Applied Therapeutics Inc. | 0.19% | 100,000 | $850K | New |
| VXRT Vaxart Inc. | 0.19% | 1,000,000 | $849K | New |
| EYPT Eyepoint Inc. | 0.18% | 100,000 | $799K | No change |
| ASND Ascendis Pharma A/S | 0.17% | 5,000 | $747K | New |
| TIL Instil Bio Inc. | 0.16% | 10,517 | $708K | New |
| ETNB 89BIO Inc. | 0.15% | 92,298 | $683K | No change |
| KPTI Karyopharm Therapeutics Inc. | 0.10% | 558,466 | $464K | No change |
| BDTX Black Diamond Therapeutics I | 0.10% | 100,000 | $435K | New |
| GUTS Fractyl Health Inc. | 0.10% | 166,666 | $422K | No change |
| ALGS Aligos Therapeutics Inc. | 0.05% | 26,219 | $227K | No change |
| VYNE THERAPEUTICS INC | 0.03% | 76,784 | $144K | Reduce -83.6% |
Options reported separately and not counted above: CCCC calls ($855K), CRBP calls ($367K), MERSANA THERAPEUTICS INC calls ($318K).
Other holdings (1): bonds, preferreds, convertibles and warrants · $7K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | 104,828 | $7K | No change |
Total filed on the 13F, all lines: $443.8M.
Portfolio Sells Q2 2024 → Q3 2024
| MORF Morphic Holding Inc. | Sold out | 0.00% | −4.09 |
| CLDX Celldex Therapeutics Inc. | Reduce -61.3% | 1.11% | −2.31 |
| URGN Urogen Pharma Ltd. | Reduce -18.2% | 2.58% | −1.99 |
| CRBP Corbus Pharmaceuticals Holdi | Sold out | 0.00% | −1.93 |
| MIRM Mirum Pharmaceuticals Inc. | Sold out | 0.00% | −0.67 |
| JSPR Jasper Therapeutics Inc. | Sold out | 0.00% | −0.62 |
| ENGN Engene Holdings Inc. | Sold out | 0.00% | −0.61 |
| FULC Fulcrum Therapeutics Inc. | Sold out | 0.00% | −0.61 |
| MERSANA THERAPEUTICS INC | Reduce -36.6% | 0.68% | −0.57 |
| ITCI Intra-Cellular Therapies Inc. | Reduce -13.1% | 2.76% | −0.50 |
| STOK Stoke Therapeutics Inc. | Sold out | 0.00% | −0.47 |
| MGNX Macrogenics Inc. | Sold out | 0.00% | −0.39 |
| KOD Kodiak Sciences Inc. | Reduce -52.9% | 0.29% | −0.32 |
| RNAM Avidity Biosciences Inc. | Reduce -8.2% | 4.92% | −0.30 |
| ZURA Zura Bio Ltd. | Sold out | 0.00% | −0.28 |
| ERAS Erasca Inc. | Reduce -11.1% | 4.27% | −0.28 |
| TRVI Trevi Therapeutics Inc. | Reduce -42.8% | 0.36% | −0.26 |
| OLMA Olema Pharmaceuticals Inc. | Reduce -16.8% | 1.22% | −0.24 |
| VYNE THERAPEUTICS INC | Reduce -83.6% | 0.03% | −0.19 |
| CCCC C4 Therapeutics Inc. | Reduce -20.4% | 1.47% | −0.17 |
| NUVL Nuvalent Inc. Class A | Reduce -20.2% | 8.56% | −0.16 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −0.15 |
| CATX Perspective Therapeutics Inc. | Reduce -35.4% | 0.51% | −0.13 |
| RLMD Relmada Therapeutics Inc. | Sold out | 0.00% | −0.07 |
| SLDB Solid Biosciences Inc. | Reduce -3.2% | 0.72% | +0.06 |
| ALNY Alnylam Pharmaceuticals Inc. | Reduce -0.6% | 2.22% | +0.06 |
| PRAX Praxis Precision Medicines I | Reduce -0.4% | 0.87% | +0.18 |
| BHVN Biohaven Ltd. | Reduce -0.4% | 1.12% | +0.26 |
Portfolio Buys Q2 2024 → Q3 2024
| INSM Insmed Inc. | Add +148.3% | 5.72% | +3.40 |
| CNTA Centessa Pharmaceuticals Ltd. | New | 2.68% | +2.68 |
| VCYT Veracyte Inc. | Add +66.7% | 3.61% | +2.10 |
| PCVX Vaxcyte Inc. | Add +2320.0% | 1.56% | +1.51 |
| PTGX Protagonist Therapeutics Inc. | New | 1.49% | +1.49 |
| VRNA Verona Pharma Ltd. | Add +14.5% | 2.26% | +1.17 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +38.4% | 3.02% | +1.15 |
| GERN Geron Corp. | Add +80.3% | 1.84% | +0.80 |
| BDSX Biodesix Inc. | Add +96.9% | 1.43% | +0.75 |
| BNTX Biontech SE-ADR | New | 0.70% | +0.70 |
| RLAY Relay Therapeutics Inc. | New | 0.67% | +0.67 |
| ORIC Oric Pharmaceuticals Inc. | Add +2.2% | 2.54% | +0.66 |
| WVE Wave Life Sciences Ltd. | Add +26.7% | 1.16% | +0.55 |
| ZVRA Zevra Therapeutics Inc. | New | 0.55% | +0.55 |
| AKRO Akero Therapeutics Inc. | Add +2.4% | 4.14% | +0.52 |
| BIOA Bioage Labs Inc. | New | 0.47% | +0.47 |
| COGT Cogent Biosciences Inc. | Add +1.3% | 2.97% | +0.46 |
| MODULAR MED INC | Add +60.0% | 0.73% | +0.38 |
| UNICYCIVE THERAPEUTICS INC | New | 0.37% | +0.37 |
| XNCR Xencor Inc. | New | 0.34% | +0.34 |
| APLT Applied Therapeutics Inc. | New | 0.19% | +0.19 |
| VXRT Vaxart Inc. | New | 0.19% | +0.19 |
| ASND Ascendis Pharma A/S | New | 0.17% | +0.17 |
| TIL Instil Bio Inc. | New | 0.16% | +0.16 |
| LBPH Longboard Pharmaceuticals Inc. | Add +1.2% | 0.93% | +0.11 |
| BDTX Black Diamond Therapeutics I | New | 0.10% | +0.10 |
| GOSS Gossamer Bio Inc. | Add +2.6% | 1.25% | +0.03 |
| IRON Disc Medicine Inc. | Add +2.6% | 1.15% | +0.02 |
| CERS Cerus Corp. | Add +2.0% | 0.59% | −0.05 |
| BBOT Bridgebio Oncology Therapeut | Add +2.7% | 1.21% | −0.05 |
| ADCT Adc Therapeutics SA | Add +1.5% | 1.27% | −0.11 |
| KALV Kalvista Pharmaceuticals Inc. | Add +2.4% | 1.50% | −0.13 |
| SRPT Sarepta Therapeutics Inc. | Add +22.0% | 1.44% | −0.20 |
| PSTX Poseida Therapeutics Inc. | Add +2.2% | 2.38% | −0.22 |
| SNDX Syndax Pharmaceuticals Inc. | Add +2.4% | 1.64% | −0.23 |
| BIIB Biogen Inc. | Add +3.0% | 0.87% | −0.24 |
| ABVX Abivax SA-ADR | Add +1.3% | 1.20% | −0.29 |
| TELA Tela Bio Inc. | Add +12.5% | 0.64% | −0.52 |
| ELUT Elutia Inc. | Add +2.6% | 1.41% | −0.55 |
| MRUS Merus NV | Add +1.9% | 7.15% | −1.96 |
Options Activity Q2 2024 → Q3 2024
| INSMED INC | call | Sold out | 250,000 | $16.8Mbefore exit |
| ALX ONCOLOGY HLDGS INC | put | Sold out | 167,900 | $1.0Mbefore exit |
| CCCC C4 Therapeutics Inc. | call | New | 150,000 | $855K |
| C4 THERAPEUTICS INC | call | Sold out | 150,000 | $693Kbefore exit |
| CRBP Corbus Pharmaceuticals Holdi | call | New | 17,800 | $367K |
| MERSANA THERAPEUTICS INC | call | Sold out | 168,300 | $338Kbefore exit |
| MERSANA THERAPEUTICS INC | call | New | 168,300 | $318K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 64 | $898.5M | ASND, CELC, COGT, URGN, IMNM |
| Q1 2026 | 66 | $848.6M | KALV, DNTH, COGT, CELC, IMNM |
| Q4 2025 | 63 | $691.1M | ABVX, COGT, URGN, KALV, CELC |
| Q3 2025 | 72 | $690.7M | ABVX, RYTM, RNAM, NUVL, URGN |
| Q2 2025 | 56 | $488.6M | MRUS, AKRO, VRNA, URGN, RYTM |
| Q1 2025 | 66 | $478.6M | VRNA, MRUS, NUVL, AKRO, INSM |
| Q4 2024 | 57 | $447.2M | NUVL, MRUS, INSM, VRNA, AKRO |
| Q3 2024 | 67 | $443.7M | NUVL, MRUS, INSM, RNAM, ERAS |
| Q2 2024 | 65 | $405.1M | MRUS, NUVL, RNAM, URGN, ERAS |
| Q1 2024 | 72 | $356.6M | MRUS, SLDB, MORF, ORIC, MERSANA THERAPEUTICS INC |